Results 91 to 100 of about 60,209 (283)

Targeted Therapies for Slow‐Flow Vascular Malformations

Australasian Journal of Dermatology, EarlyView.
ABSTRACT Advances in genetic sequencing technologies have enabled the identification of key activating somatic variants in cellular signalling pathways involved in the pathogenesis of vascular malformations. Given that these genetic variants are also implicated in the pathogenesis of several cancers, the repurposing of targeted therapies developed in ...
Grace X. Li, Deshan F. Sebaratnam, James P. Pham   +2 more
wiley   +1 more source

On the role of specific drug binding in modelling arterial eluting stents [PDF]

, 2016
In this paper we consider drug binding in the arterial wall following delivery by a drug-eluting stent. Whilst it is now generally accepted that a non-linear saturable reversible binding model is required to properly describe the binding process, the ...
AR Tzafriri, AR Tzafriri, CM Groh, DA Lauffenburger, F Bozsak, F Bozsak, G Frenning, G Pontrelli, GD Dangas, Giuseppe Pontrelli, RI Hickson, S McGinty, Sean McGinty, TTN Vo   +13 more
core   +1 more source

Therapeutic drug monitoring of tacrolimus after kidney transplantation: trough concentration or area under curve‐based monitoring?

British Journal of Clinical Pharmacology, EarlyView.
Abstract Measurement of pre‐dose tacrolimus concentrations, also referred to as trough concentrations or C0 (in this paper the term C0 will be used), is the most frequently used parameter for therapeutic drug monitoring in patients after solid organ transplantation. C0 is relatively easy to obtain, and can be combined with other lab tests.
Teun van Gelder, Armin Gelinck, Soufian Meziyerh, Aiko P. J. de Vries, Dirk Jan A. R. Moes   +4 more
wiley   +1 more source

Sirolimus-induced pneumonitis

Indian Journal of Nephrology, 2007
Rapamycin is increasingly being used as calcineurin-inhibitor-sparing immunosuppressive drug. We report a case who presented with fever, breathlessness and bilateral crackles in the chest 6 weeks after administering rapamycin. Chest skiagram showed right-sided pneumonitis and bronchoalveolar lavage was negative for infective pathogens.
SR Gadela, PP Varma, AK Rajput, AK Hooda
openaire   +2 more sources

Killing several birds with one stone: A multi‐indication population pharmacokinetic model and Bayesian estimator for enteric‐coated mycophenolate sodium

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Mycophenolic acid (MPA), the active component of enteric‐coated mycophenolate sodium (EC‐MPS), exhibits highly variable pharmacokinetics. Only a few population pharmacokinetic (popPK) models and Bayesian estimators (MAP‐BE) exist for estimating MPA AUC and all in renal transplantation.
Yeleen Fromage, Hamza Sayadi, Kevin Koloskoff, Pierre Marquet, Marc Labriffe, Caroline Monchaud, Jean‐Baptiste Woillard   +6 more
wiley   +1 more source

Experimental rat models of chronic allograft nephropathy: a review [PDF]

, 2014
Chronic allograft nephropathy (CAN) is the leading cause of late allograft loss after renal transplantation (RT), which continues to remain an unresolved problem. A rat model of CAN was first described in 1969 by White et al. Although the rat model of RT
Haylor, John, Shrestha, Badri
core   +2 more sources

Transferrin Receptor Promotes Endometrial Cancer Proliferation by Activating the Iron‐Dependent PI3K/AKT/mTOR Signaling Pathway

Cancer Science, EarlyView.
TFRC may serve as a critical prognostic indicator for risk assessment in EC patients and propose TFRC as a promising therapeutic target to impede EC progression. The upregulation of TFRC‐mediated iron absorption facilitated the proliferation of EC, suggesting that iron chelators had the potential to be a promising therapeutic agent for the treatment of
Yufei Yang, Ying Ning, Yu Chen, Tian Tian, Xinyan Gao, Yan Kong, Ke Lei, Zhumei Cui   +7 more
wiley   +1 more source

Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients

Journal of Lipid Research, 2002
Sirolimus (Rapammune®, rapamycin, RAPA) is a potent immunosuppressive drug that reduces renal transplant rejection. Hyperlipidemia is a significant side effect of sirolimus treatment, and frequently leads to cardiovascular disease.
Joel D. Morrisett, Ghada Abdel-Fattah, Ron Hoogeveen, Eddie Mitchell, Christie M. Ballantyne, Henry J. Pownall, Antone R. Opekun, Jonathon S. Jaffe, Suzanne Oppermann, Barry D. Kahan   +9 more
doaj  

The Economic Consequences of Sirolimus Treatment in Patients With Vascular Malformations

Journal of Vascular Anomalies
Objectives:. Sirolimus is one of the first oral drugs for safe and effective treatment of patients with vascular malformations, and may save (expensive) interventions.
Veroniek E. M. Harbers, Wietske Kievit, Raquel Duque Jimenez, Leo J. Schultze Kool, Ingrid M. P. van Rijnsoever, Bas H. Verhoeven, Carine J. M. van der Vleuten, D. Maroeska W. M. te Loo, Members of the Vascular Anomalies Working Group (VASCA WG) of the European Reference Network for Rare Multisystemic Vascular Diseases (VASCERN)—Project ID: 769036   +8 more
doaj   +1 more source

Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing. [PDF]

, 2014
Understanding genetic aberrations in cancer leads to discovery of new targets for cancer therapies. The genomic landscape of hepatocellular carcinoma (HCC) has not been fully described. Therefore, patients with refractory advanced/metastatic HCC referred
Janku, Filip, Kaseb, Ahmed O, Kurzrock, Razelle, Tsimberidou, Apostolia M, Wolff, Robert A   +4 more
core   +3 more sources